Yebo, imibhede yokwelapha ngokukhanya okubomvu (RLT) ngokuvamile ibhekwa njengephephile uma isetshenziswa kahle futhi inemiphumela emibi emincane. Kodwa-ke, ukuphepha kuncike ezintweni ezifana nekhwalithi yedivayisi, isikhathi sokuvezwa kanye nezimo zempilo zomuntu ngamunye. Nansi incazelo eningiliziwe:
Izici zokuphepha zemibhede yokwelapha ngokukhanya okubomvu
Akukho misebe ye-UV
Ngokungafani nemibhede yokushiswa kwesikhumba, imibhede ye-RLT isebenzisa ama-LED akhipha ukukhanya okubomvu kuphela (630-700 nm) kanye nokukhanya okuseduze kwe-infrared (800-900 nm). Lawa maza okukhanya awanayo imisebe ye-UV elimaza i-DNA ehlotshaniswa nomdlavuza wesikhumba.
Akushisi futhi akuhlaseli
Ukukhanya kuphansi (LLLT), okusho ukuthi akushisi noma akushisi isikhumba. Kuvunyelwe yi-FDA ukuqeda ubuhlungu nokwelapha isikhumba.
I-FDA iyivumile ukusetshenziswa kwayo kwezinye izindlela.
Amanye amadivayisi avunyelwe ukwelapha izimo ezifana nobuhlungu bemisipha namalunga, induna kanye nokulahlekelwa izinwele (isib. iJoovv kanye neCelluma). Hlola ukuthi i-FDA 510(k) clearance iyasebenza yini.
Imiphumela emibi emincane:
Okungavamile futhi okuthambile: ukukhathala kwamehlo okwesikhashana, ukoma noma ukubomvu okuncane (gwema ukubonakala emehlweni ngqo - gqoka izibuko zamehlo).
Izingozi ezingaba khona kanye nezinyathelo zokuphepha:
Ukuphepha kwamehlo:
Ukuchayeka isikhathi eside ekukhanyeni okubomvu/okuseduze kwe-infrared (NIR) kungabangela ukucindezeleka kwe-retina. Sebenzisa njalo izibuko zokuzivikela, ikakhulukazi emibhedeni enamandla amakhulu.
Ukuzwela Kwesikhumba:
Abantu abanezinkinga zokuzwela ukukhanya (isb. i-lupus noma i-porphyria) noma abathatha imithi yokuzwela ukukhanya (isb. ama-antibiotic noma i-Accutane) kufanele baqale baxhumane nodokotela.
Ukusebenzisa ngokweqile:
Okuningi akuhlali kungcono. Izikhathi eziningi (isb. imizuzu engaphezu kwengu-20 ngosuku) zinganciphisa izinzuzo noma zibangele ukucasuka. Namathela eziqondisweni zomenzi.
Izinkinga ze-thyroid:
Ukukhanya kwe-NIR kungathinta ukusebenza kwe-thyroid kwabanye abantu. Labo abane-hyperthyroidism kufanele baqaphele izimpawu zabo.
Ukukhulelwa:
Ucwaningo oluncane lukhona. Njengesinyathelo sokuqapha, abesifazane abakhulelwe bavame ukwelulekwa ukuthi bagweme ukwelashwa ngokukhanya okubomvu komzimba wonke (i-RLT).
Ubani okufanele agweme imibhede yokwelapha ngokukhanya okubomvu?
Abantu abanomdlavuza wesikhumba osebenzayo (kunengozi yokuvuselela amangqamuzana anomdlavuza).
Labo abasebenzisa imithi ebangela ukuzwela kwelanga (isib. i-tetracyclines noma i-retinoids).
Abantu abanesifo sokuwa (izibani ezikhanyayo zingase zibangele ukuquleka ezimweni ezingavamile).
Indlela yokusebenzisa ngokuphephile:
Khetha idivayisi ethembekile.
Khetha imikhiqizo eqinisekiswe yi-FDA noma ehlolwe ngokwezokwelapha (isb. iMerican). Gwema amamodeli ashibhile, angaqinisekisiwe.
Landela iziqondiso zesikhathi/ibanga.
Isikhathi esivamile sithatha imizuzu eyi-10-20 ebangeni elingamasentimitha ayi-12-12 ukusuka embhedeni, izikhathi ezi-3-5 ngesonto.
Vikela amehlo akho:
Gqoka izibuko eziphuzi noma ezikhanyayo ezenzelwe i-RLT.
Ukuhlolwa kwe-patch kuqala.
Zama indawo encane ukuhlola ukusabela kwesikhumba.
Ukuvumelana kwesayensi:
Ukubuyekezwa kuka-2023 ku-Photobiomodulation, Photomedicine, kanye ne-Laser Surgery kuqinisekisile ukuthi i-RLT iphephile kubasebenzisi abaningi uma kulandelwa izinqubo.
Azikho izingozi zesikhathi eside eziye zatholakala eminyakeni eminingi esetshenziswa, kodwa ucwaningo luyaqhubeka.
Iphuzu elibalulekile:
Imibhede yokwelapha ngokukhanya okubomvu iyingozi encane kubantu abaningi, kodwa kufanele uthintane nodokotela uma unezinkinga ezithile zempilo. Namathela kumadivayisi asezingeni eliphezulu kanye neziqondiso zokusebenzisa ezifanele.